Gilead Sciences, Inc. (GILD) Competitors & Peers
The 5 largest companies in the same industry as Gilead Sciences, Inc., by market value — each comparable links to its own dossier. Numbers are code-computed, never estimated.
| Ticker | Relationship | Price | Comparables |
|---|---|---|---|
| LLY | Peer | $1,411.95 | P/E 45.8RSI 68Cap 1.33 T |
| JNJ | Peer | $282.11 | P/E 42.8RSI 64Cap 679.1 B |
| ABBV | Competitor | $293.30 | P/E 50.4RSI 62Cap 518.2 B |
| MRK | Peer | $148.76 | P/E 150.3RSI 54Cap 367.4 B |
| AZN | Peer | $189.39 | P/E 26.8RSI 68Cap 288.8 B |
How these relationships were derived
Every relationship below carries its provenance. A confirmed edge is sourced from a public filing or disclosure and links to it; an AI-inferred edge is surfaced by the relationship model and is unverified — shown for color, not as evidence.
Confirmed relationships (cited)
Sourced from a public filing or disclosure — each links to its origin.
- ASMBSupplier
Own 10-K customer-concentration disclosure: GileadSciencesIncorporated = 100% of revenue.
Confirmed — SEC filing / public disclosuresec.gov ↗ - CORSupplier
Cencora is one of Gilead's three primary wholesale distributors, part of the ~90% US gross product sales concentration.
Confirmed — SEC filing / public disclosuresec.gov ↗ - MCKSupplier
McKesson is one of Gilead's three primary wholesale distributors, accounting for approximately 20-21% of Gilead's revenues.
Confirmed — SEC filing / public disclosuresec.gov ↗ - CAHSupplier
Cardinal Health is one of Gilead's three primary wholesale distributors, part of the ~90% US gross product sales concentration.
Confirmed — SEC filing / public disclosuresec.gov ↗ - MGNXSupplier
Own 10-K customer-concentration disclosure: GileadSciencesInc = 11% of revenue.
Confirmed — SEC filing / public disclosuresec.gov ↗
Model-inferred relationships (unverified)
Suggested by the relationship model, with no public source on file. Treat each as a lead worth checking, not as evidence.
- TNGXPartner
Tango partners with Gilead on drug discovery and trials.
Model-inferred, unverified — treat as a lead, not evidence - IDYAPartner
Gilead is a strategic partner holding opt-in rights and co-development programs for IDEAYA's synthetic lethality pipeline.
Model-inferred, unverified — treat as a lead, not evidence - RCUSPartner
Gilead is a strategic partner holding opt-in rights and co-development options for Arcus's oncology candidates.
Model-inferred, unverified — treat as a lead, not evidence - ABBVCompetitor
Gilead and AbbVie are the two dominant players in HIV treatment globally — Gilead's Biktarvy (BIC/FTC/TAF) vs AbbVie's Kaletra and legacy protease inhibitor regimens.
Model-inferred, unverified — treat as a lead, not evidence - VRTXCompetitor
CF + virology overlap historically.
Model-inferred, unverified — treat as a lead, not evidence